Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
Javier De CastroAmelia InsaRoberto Collado-BorrellVicente Escudero-VilaplanaAlex MartínezElena FernandezIvana SullivanNatalia ArrabalDavid CarcedoAlba ManzanequePublished in: BMC pulmonary medicine (2023)
To our knowledge, this is the first study that specifically quantifies the cost of relapse in NSCLC in Spain. Our findings shown that the overall cost of a relapse after appropriate treatment of early-stage NSCLC patients is substantial, and it increases considerably in the metastatic relapse setting, mainly due to the high cost and long duration of first-line treatments.
Keyphrases
- early stage
- small cell lung cancer
- end stage renal disease
- squamous cell carcinoma
- free survival
- chronic kidney disease
- newly diagnosed
- healthcare
- ejection fraction
- advanced non small cell lung cancer
- sentinel lymph node
- prognostic factors
- brain metastases
- locally advanced
- radiation therapy
- lymph node
- neoadjuvant chemotherapy
- rectal cancer